Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Third Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
Front Immunol. 2020 Oct 9;11:563653. doi: 10.3389/fimmu.2020.563653. eCollection 2020.
Identification of reliable biomarkers to predict efficacy of immune checkpoint inhibitors and to monitor relapse in cancer patients receiving this therapy remains one of the main objectives of cancer immunotherapy research. We found that the pretreatment B cell number in the peripheral blood differed significantly between responders and non-responders to anti-PD-1-based immunotherapy. Patients with various cancer types achieving a clinical response had a significantly lower number of B cells compared with those with progressive disease. Patients who progressed from partial response to progressive disease exhibited a gradually increased number of circulating B cells. Our findings suggest that B cells represent a promising biomarker for anti-PD-1-based immunotherapy responses and inhibit the effect of PD-1 blockade immunotherapy. Thus, preemptive strategies targeting B cells may increase the efficacy of PD-1 blockade immunotherapy in patients with solid tumors.
确定可靠的生物标志物来预测接受免疫检查点抑制剂治疗的癌症患者的疗效，并监测其复发情况，仍然是癌症免疫治疗研究的主要目标之一。我们发现，对基于抗 PD-1 的免疫治疗有反应者和无反应者之间，外周血中的 B 细胞数量存在显著差异。与疾病进展患者相比，实现临床缓解的各种癌症类型患者的 B 细胞数量明显较低。从部分缓解进展为疾病进展的患者表现出循环 B 细胞数量逐渐增加。我们的研究结果表明，B 细胞是一种很有前途的基于抗 PD-1 的免疫治疗反应的生物标志物，并抑制 PD-1 阻断免疫治疗的效果。因此，针对 B 细胞的预防策略可能会提高 PD-1 阻断免疫治疗在实体瘤患者中的疗效。
